Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 127-134

  Fragoulakis, Vassilis ^a   Kourlaba, Georgia ^a   Goumenos, Dimitris ^b   Konstantoulakis, Manousos ^c   Maniadakis, Nikolaos ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b Department of Medicine University Hospital of Patras ^*  (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anemia; Cost minimization; Economic evaluation; Ferric carboxymaltose; Iron therapy

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; IRON; IRON DEXTRAN;

ABDOMINAL PAIN; ARTICLE; BACKACHE; CONSTIPATION; COST CONTROL; COST MINIMIZATION ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DYSPNEA; ECONOMIC EVALUATION; FATIGUE; FEVER; GREECE; HEADACHE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; INJECTION SITE REACTION; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MUSCLE CRAMP; NATIONAL HEALTH SERVICE; NAUSEA; PHYSICAL PERFORMANCE; QUALITY OF LIFE; RASH; SURGICAL PATIENT; THORAX PAIN; VOMITING; WORK CAPACITY;

EID: 84930478852     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S30514     Document Type: Article

References (38)

1. Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol. 2012;24(2): 109-116.
2. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309-1316.
3. Goonewardene M, Shehata M. Anaemia in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2012;26(1):3-24.
4. Kent AJ, Blackwell VJ, Travis SP. What is the optimal treatment for anemia in inflammatory bowel disease? Curr Drug Deliv. October 21, 2011. [Epub ahead of print.]
5. Cavill I, Auerbach M, Bailie GR, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin. 2006;22(4):731-737.
6. Pasricha SR. Should we screen for iron deficiency anaemia? A review of the evidence and recent recommendations. Pathology. 2012;44(2):139-147.
7. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121-132.
8. de Benoist B, McLean E, Egli I, et al. Worldwide prevalence of anaemia 1993-2005: WHO Global Database. Geneva: World Health Organization;2008. Available from: http://whqlibdoc.who.int/ publications/2008/9789241596657_eng.pdf. Accessed March, 8 2012.
9. Marantidou O, Loukopoulou L, Zervou E, et al. Factors that motivate and hinder blood donation in Greece. Transfus Med. 2007;17(6):443-450.
10. Kanavos P, Yfantopoulos J, Vandoros C, Politis C. The economics of blood: gift of life or a commodity? Int J Technol Assess Health Care. 2006;22(3):338-343.
11. Crichton R, Danielson BG, Geisser P. Iron Therapy with Special Emphasis on Intravenous Administration. 4th ed. London, UK: International Medical Publishers; 2008.
12. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182-1192.
13. Gordon SS, Hadley PE, Van Wyck DB, et al. Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding Obstet Gynecol. 2007;109(Suppl 4):108S.
14. Qunibi WY, Martinez C, Smith M, et al. Efficacy and safety of IV ferric carboxymaltose (FCM) compared to oral iron in anemic patients with non-dialysis-dependent CKD. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association. Stockholm; 2008.
15. Schaefer RM, Khasabov NN, Todorov NG, et al. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia Paper presented at: 45th Congress of the European Renal Association and the European Dialysis and Transplant Association. Stockholm; 2008.
16. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008; 101(1):67-73.
17. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):267-278.
18. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435. e1-e7.
19. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4.
20. Ministry of Health and Social Solidarity [homepage on the Internet]. 2012. Available from: http://www.yyka.gov.gr. Accessed December 17, 2011.
21. Vifor France SA. Ferinject Summary of Product Characteristics. 2009; http://www.medicines.org.uk/EMC/medicine/24167/SPC/Ferinject+ (ferric+carboxymaltose). Accessed September 15, 2011.
22. Vifor (International) Inc. Venofer (iron sucrose injection USP). http://www.medicines.org.uk/EMC/medicine/24168/SPC/Venofer+ (iron+sucrose)/. Accessed September 15, 2011.
23. Pharmacosmos A/S. Cosmofer Summary of Product Characteristics. 2010; http://www.medicines.org.uk/emc/medicine/14139/SPC/ CosmosFer/. Accessed September 15, 2011.
24. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag. 2011;7:103-113.
25. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-756.
26. Hellenic Statistical Authority. Available from: http://www.statistics.gr. Accessed September 15, 2011.
27. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis. 1998;31(1):81-86.
28. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol. 2011;86(10):860-862.
29. Maniadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin. 2009;25(3):797-805.
30. National Institute for Health and Clinical Excellence, June 2008, available from: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf. Guide to the Methods of Technology Appraisal. Accessed March 12, 2011.
31. Willan AR. Statistical analysis of cost-effectiveness data from randomized clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2006;6(3):337-346.
32. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11(7):565-574.
33. Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health. 2005;8(2):149-156.
34. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8(6):629-638.
35. Brock E, Braunhofer P, Troxler J. Real-life budget impact (BI) of parenteral iron treatment of iron deficiency in Switzerland. ISPOR 13th Annual European Congress November 9 2010; Prague-Poster No PSY12.
36. Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis. 2010;4(4):427-430.
37. Pugh-Clarke K, Cooper L, Turner J, Fermin J. An evidence-based approach to anaemia management in predialysis chronic kidney disease. J Ren Care. 2009;35 Suppl 2:29-31.
38. Garcia-Erce JA, Diez-Lobo AI, Munoz M. multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107(3):477-478.